From L-R: Reps. Raja Krishnamoorthi (D-IL) and Mike Gallagher (R-WI), and Ginkgo co-founder Tom Knight meet at Ginkgo's headquarters to discuss Chinese competition in biotech (Nicole DeFeudis for Endpoints News)

February 13, 2024 03:07 PM EST

Manufacturing

Lawmakers call for US investigation of Chinese contract research giants

Nicole DeFeudis

Editor

Four bipartisan lawmakers have urged the US government to investigate contract research and manufacturing giants WuXi AppTec and WuXi Biologics for alleged Chinese military ties …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lawmakers call for US investigation of Chinese contract research giants

Nicole DeFeudis

Editor

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Law­mak­ers call for US in­ves­ti­ga­tion of Chi­nese con­tract re­search gi­ants

Nicole DeFeudis

Editor

Sign up to read this article for free.

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Lawmakers call for US investigation of Chinese contract research giants

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?